Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > CLVS Clovis Oncology > Detailed Quotes

CLVS Clovis Oncology

1.216
-0.084-6.46%
Trading Session 10/05 10:56 ET
High
1.300
Open
1.280
Turnover
517.83K
Low
1.210
Pre Close
1.300
Volume
414.96K
Market Cap
175.69M
P/E(TTM)
Loss
52wk High
4.760
Shares
144.48M
P/E(Static)
Loss
52wk Low
0.581
Float Cap
170.53M
Bid/Ask %
-10.00%
Historical High
116.750
Shs Float
140.24M
Volume Ratio
0.61
Historical Low
0.581
Dividend TTM
--
Div Yield TTM
--
P/B
-0.48
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.30%
Amplitude
6.92%
Avg Price
1.247
Lot Size
1
Float Cap
170.53M
Bid/Ask %
-10.00%
Historical High
116.750
Shs Float
140.24M
Volume Ratio
0.61
Historical Low
0.581
Dividend TTM
--
P/B
-0.48
Dividend LFY
--
Turnover Ratio
0.30%
Amplitude
6.92%
Avg Price
1.247
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
CEO: Mr. Patrick J. Mahaffy
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...